CAMBRIDGE, England—Inotec AMD, a medical equipment manufacturer, announced the close of its $33 million Series C financing round. The company said this funding—led by investors Amadeus Capital Partners, Meltwind, Puhua Capital and the Wealth Club—intends to further its mission to heal chronic wounds and improve patients’ lives on a global scale.
The company said the proceeds from this funding round will be used to secure national reimbursement in the U.S. for the company’s advanced wound care product “Natrox O2,” as well as to ensure broader product accessibility for patients across the U.S. Additionally, the company said the funds aim to support its leadership team expansion and strengthen its global growth.
“Inotec AMD’s global success is rooted in our dedication to patient-centric innovation, especially through our work with Natrox O2,” said Craig Kennedy, CEO of Inotec AMD. “This latest round of financing underscores the confidence our investors have in our vision, and our ability to make a significant impact in the wound care space providing life-altering improvements for our patients.”
With the new funding, the company intends to obtain national U.S. reimbursement for Natrox O2, in an effort to enable greater adoption of continuous topical oxygen therapy (cTOT) technology. The company said this reimbursement would aim to allow health care providers to offer user-friendly therapy designed to accelerate healing.
“Amadeus backed Natrox from inception, and it is fulfilling to see this best-in-class technology now available in a growing number of markets. Natrox O2 is already authorized to sell in 46 countries,” said Pierre Socha, partner at Amadeus Capital Partners. “It is becoming the reference advance therapy for the healing of chronic wounds across private and public health systems globally. Securing national coverage in the US is another step forward for the team.”
